Senior Medical Science Liaison; PA, NJ

Supporting Territory:
Pennsylvania & New Jersey About Summit

Ivonescimab, known as SMT
112, is a novel, potential first‑in‑class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD‑1 with the anti‑angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when both PD‑1 and VEGF are present.

Summit has begun its clinical development of ivonescimab in non‑small cell lung cancer (NSCLC), with three active Phase III trials:

• HARMONi – a Phase III trial evaluating ivonescimab combined with chemotherapy versus placebo plus chemotherapy in patients with EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC who progressed after 3rd‑generation EGFR TKI (eg, osimertinib).
• HARMONi‑3 – a Phase III trial evaluating ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy in patients with first‑line metastatic NSCLC.
• HARMONi‑7 – a Phase III trial evaluating ivonescimab monotherapy versus pembrolizumab monotherapy in patients with first‑line metastatic NSCLC whose tumors have high PD‑L1 expression.

Ivonescimab is investigational and not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. It received marketing authorization in China in May 2024 and was granted Fast Track designation by the FDA for the HARMONi clinical trial setting.

The Senior Medical Science Liaison (MSL) is a field‑based scientific expert who strategically supports Summit’s cancer therapeutic objectives across the product life cycle. The MSL is the primary communicator of Summit’s science within a specific geography, building relationships with healthcare professionals (HCPs) and providing disease‑state, therapeutic‑landscape, and product education.

• Develop, execute, and maintain high‑impact territory plans, including HCP and investigator engagement plans aligned with therapeutic‑area objectives.
• Support clinical development and research initiatives, including site evaluation, recruitment, investigator meetings, external expert identification, and generation of scientific data through investigator‑sponsored trials.
• Identify, gain access to, and develop professional, customer‑centric relationships with external experts in Immuno‑Oncology within the assigned geography.
• Provide education on disease state, therapeutic landscape, and Summit products across the product lifecycle to HCPs and researchers.
• Participate in and report insights from scientific meetings and other relevant events.
• Continuously self‑educate on market issues, product knowledge, and therapeutic advances.
• Actively participate in team meetings, organizational activities, and country‑driven medical affairs activities (e.g., advisory boards, masterclasses, round tables).
• Create, maintain, and collaborate on cross‑functional relationships to develop and execute account plans that support shared scientific or business objectives.
• All other duties as assigned.

• Doctoral degree in the health sciences from an accredited university (MD, PhD, Pharm
  
  D, or equivalent) required. Significant clinical and/or industry experience in oncology may be accepted in lieu of the graduate degree.
• Minimum of 5+ years of solid‑tumor cancer experience.
• Minimum of 5+ years of clinical, scientific/research, or industry‑related experience.
• Minimum of 2+ years’ experience in a Medical Science Liaison role.
• Previous pharmaceutical industry experience within the relevant scientific discipline strongly preferred.
• Past achievements in:
  • Understanding, analyzing, and communicating complex scientific concepts and data.
  • Building credible relationships with prominent HCPs.
  • Independently identifying and translating corporate needs into actionable plans.
  • Self‑motivation to achieve and exceed goals.
  • Problem‑solving and analytic skills.
  • Critical thinking.
  • Ability to work independently.
• Must meet Health Care Industry Representative (HCIR) credentialing requirements to access facilities in…